AIMD NASDAQ

Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.